FDA

Latest News

freshidea-stock.adobe.com
May 29th 2024
FDA Sets Date for Zanidatamab in Bile Duct Cancer

Zanidatamab is bispecific antibody that targets HER2 in patients with metastatic biliary tract cancer. The FDA has set an action date of Nov. 29, 2024.

Kanisorn-stock.adobe.com
May 29th 2024

FDA Assigns Review Date for Inavolisib in Metastatic Breast Cancer

Anusorn-stock.adobe.com
May 29th 2024

FDA Approves First Interchangeable Biosimilar of Soliris